var data={"title":"Interferon beta-1a: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Interferon beta-1a: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6379?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=interferon-beta-1a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Interferon beta-1a: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183458\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Avonex;</li>\n      <li>Avonex Pen;</li>\n      <li>Rebif;</li>\n      <li>Rebif Rebidose;</li>\n      <li>Rebif Rebidose Titration Pack;</li>\n      <li>Rebif Titration Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183459\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Avonex;</li>\n      <li>Rebif</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183497\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183461\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis (MS):</b> <b>Note:</b> Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM (Avonex):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>US labeling:</i> 30 mcg once weekly; to decrease flu-like symptoms, may initiate once-weekly dosing with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg  once weekly (weeks 2 to 4) up to recommended dose (30 mcg once weekly)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Canadian labeling:</i> 30 mcg once weekly; to decrease flu-like symptoms, may initiate once-weekly dosing with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg once weekly (weeks 2 to 4) or once every 2 weeks (to week 7) up to recommended dose (30 mcg once weekly).  In progressive relapsing MS or secondary progressive MS with recurrent neurologic dysfunction may consider increasing to 60 mcg once weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ (Rebif): Target dose is either 22 or 44 mcg 3 times weekly; doses should be separated by at least 48 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Target dose 44 mcg 3 times weekly: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial: 8.8 mcg (20% of target dose) 3 times weekly for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Titration: 22 mcg (50% of target dose) 3 times weekly for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Target dose: 44 mcg 3 times weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Target dose 22 mcg 3 times weekly:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial: 4.4 mcg (20% of target dose) 3 times weekly for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Titration: 11 mcg (50% of target dose) 3 times weekly for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Target dose: 22 mcg 3 times weekly</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;text-align:justify;\">\n      <b>Single demyelinating event (Canadian labeling [Rebif]; not in US labeling):</b> SubQ:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">\n      <b>Target dose 44 mcg 3 times weekly: Note:</b> Analgesics and/or antipyretics prior to and for 24 hours after dosing may help decrease flu-like symptoms:</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">Initial: 8.8 mcg (20% of target dose) 3 times weekly for 2 weeks</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">Titration: 22 mcg (50% of target dose) 3 times weekly for 2 weeks</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">Target dose: 44 mcg 3 times weekly </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183462\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14385980\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183463\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution in patients with active liver disease, alcohol abuse, ALT &gt;2.5 x ULN, or a history of significant liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14385978\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Autoimmune disorder development: Consider discontinuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Depression or other severe psychiatric symptoms: Consider discontinuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hepatotoxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">ALT &gt;5 x ULN: Temporarily discontinue therapy or consider dose reduction until ALT normalizes, then may consider retitration of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Symptomatic (eg, jaundice): Discontinue immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Leukopenia: May require temporary discontinuation or dose reduction until resolution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183440\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avonex: 30 mcg [contains albumin (human), mouse (murine) and/or hamster protein; supplied with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avonex: 30 mcg/0.5 mL (0.5 mL) [albumin free; contains mouse (murine) and/or hamster protein; prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avonex Pen:  30 mcg/0.5 mL (0.5 mL) [albumin free; contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebif: 22 mcg/0.5 mL (0.5 mL), 44 mcg/0.5 mL (0.5 mL) [contains albumin (human), mouse (murine) and/or hamster protein; prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebif Rebidose: 22 mcg/0.5 mL (0.5 mL), 44 mcg/0.5 mL (0.5 mL) [contains albumin (human), mouse (murine) and/or hamster protein; autoinjector]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [preservative free, combination package]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebif Titration Pack: 8.8 mcg/0.2 mL (6s) and 22 mcg/0.5 mL (6s)  [contains albumin (human), mouse (murine) and/or hamster protein; prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebif Rebidose Titration Pack: 8.8 mcg/0.2 mL (6s) and 22 mcg/0.5 mL (6s)  [contains albumin (human), mouse (murine) and/or hamster protein; autoinjector]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183424\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874830\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Avonex: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf#page=21&amp;token=NvbnEUWbogizDjOnYEJkIHWqA+W40myhAh4WjAljg3/aOGqlT7sHW+8wFX9pI0cQJ1UWcV37GN7SrNHRit32kKooFWooqQaExYHdyeR9Yk0X7DzqumGgudBw/EeJMrVf&amp;TOPIC_ID=8565\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rebif: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089019.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlx4DpLKYqXED/W0CQaoX6Sg==&amp;TOPIC_ID=8565\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089019.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183442\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">The first injection should be administered under the supervision of a health care professional.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Avonex: Administer IM; rotate injection site; do not inject into area where skin is irritated, red, bruised, scarred, or infected. Two hours after injection, examine site for redness, swelling, or tenderness. Discard any unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rebif: Administer SubQ at the same time of day on the same 3 days each week (eg, Mon, Wed, Fri), preferably in the late afternoon or evening; doses should be at least 48 hours apart; rotate injection site; do not inject into area where skin is irritated, red, bruised, or scarred. Discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183441\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>US labeling:</b> Treatment of relapsing forms of multiple sclerosis (MS) to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Canadian labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of relapsing forms of multiple sclerosis (MS) to decrease the frequency of clinical exacerbations, delay the accumulation of physical disability, reduce the requirement for steroids, reduce the number of hospitalizations, and reduce disease burden</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">To decrease the number and volume of active brain lesions, decrease overall disease burden, and delay onset of clinically definite MS in patients who have experienced a single demyelinating event</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183506\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avonex may be confused with Avelox</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183431\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported as a composite of both commercially-available products. Spectrum and incidence of reactions is generally similar between products, but consult individual product labels for specific incidence.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (58% to 70%), fatigue (33% to 41%), depression (18% to 25%), pain (23%), chills (19%), dizziness (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (23%), abdominal pain (8% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (28% to 36%), lymphadenopathy (11% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (20% to 27%), increased serum AST (10% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (neutralizing; significance not known; Rebif: 24% to 31%; Avonex: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (3% to 92%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (25% to 29%), back pain (23% to 25%), weakness (24%), skeletal pain (10% to 15%), rigors (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (49% to 59%), sinusitis (14%), upper respiratory tract infection (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (20% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (5% to 8%), vasodilation (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hypertonia (6% to 7%), migraine (5%), ataxia (4% to 5%), drowsiness (4% to 5%), malaise (4% to 5%), seizure (1% to 5%), suicidal tendencies (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythematous rash (5% to 7%), maculopapular rash (4% to 5%), alopecia (4%), hyperhidrosis (4%), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Thyroid disease (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (1% to 5%), toothache (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency (2% to 7%), urinary incontinence (2% to 4%), urine abnormality (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (2% to 8%), anemia (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (8%), bruising at injection site (6%), inflammation at injection site (6%), tissue necrosis at injection site (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease (4%), xerophthalmia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormal healing, abnormal hepatic function tests, abscess, abscess at injection site, amnesia, anaphylaxis, angioedema, anxiety, arteritis, arthritis, ascites, autoimmune hepatitis, basal cell carcinoma, Bell's palsy, bloody stools, breast fibroadenosis, cardiac arrhythmia, cardiac failure, cardiomyopathy, cellulitis, cellulitis at injection site, clumsiness, cold and clammy skin, colitis, confusion, conjunctivitis, constipation, contact dermatitis, dehydration, depersonalization, dermal ulcer, diaphoresis, diverticulitis, drug dependence, dyspnea, dysuria, ecchymoses, emotional lability, emphysema, epididymitis, erythema, erythema multiforme, eye pain, facial edema, facial paralysis, fibrocystic breast changes, fibrosis at injection site, furunculosis, gallbladder disease, gastritis, gastrointestinal hemorrhage, genital pruritus, gingival hemorrhage, gingivitis, gynecomastia, hematuria, hemolytic-uremic syndrome, hemoptysis, hemorrhage, hepatic failure, hepatic injury, hepatic neoplasm, hepatitis, hepatomegaly, hepatotoxicity (idiosyncratic) (Chalasani 2014), hernia, hiccups, hyperesthesia, hypermenorrhea, hypersensitivity reaction at injection site, hyperthyroidism, hyperventilation, hypoglycemia, hypokalemia, hypomagnesemia, hypotension, hypothyroidism, immune thrombocytopenia, increased appetite, increased coagulation time, increased libido, increased thirst, intestinal obstruction, intestinal perforation, labyrinthitis, laryngitis, leukorrhea, lipoma, lump in breast, lupus erythematosus, menopause, myasthenia, neoplasm, nephrolithiasis, neurological signs and symptoms (transient; may mimic multiple sclerosis exacerbations), nevus, nocturia, orolingual edema, orthostatic hypotension, osteonecrosis, otalgia, palpitations, pancytopenia, paresthesia, pelvic inflammatory disease, penile disease, pericarditis, periodontal abscess, periodontitis, peripheral ischemia, peripheral vascular disease, petechia, Peyronie disease, pharyngeal edema, pneumonia, polyuria, postmenopausal bleeding, proctitis, prostatic disease, pruritus, psychiatric disturbance (new or worsening; including suicidal ideation), psychoneurosis, pulmonary embolism, pulmonary hypertension (Govern 2015; Health Canada Nov. 2, 2016), pyelonephritis, renal pain, retinal vascular disease, seborrhea, sepsis, severe weakness (transient), skin blister, skin discoloration, skin photosensitivity, skin rash, spider telangiectasia, Stevens-Johnson syndrome, synovitis, tachycardia, telangiectasia, testicular disease, thromboembolism, thrombotic thrombocytopenic purpura, tongue disease, urethral pain, urinary retention, urinary urgency, uterine fibroids, uterine hemorrhage, vaginal hemorrhage, vascular disease, vesicular eruption, vitreous opacity, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183445\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to natural or recombinant interferon beta, human albumin (albumin-containing formulations only), or any other component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Rebif: Pregnancy; decompensated liver disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183428\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions, including anaphylaxis, have been reported. Some reactions may occur after prolonged use. Discontinue therapy if anaphylaxis or other allergic reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorders: Autoimmune disorders including idiopathic thrombocytopenia, hyper- and hypothyroidism and rarely autoimmune hepatitis have been reported. Consider discontinuation of treatment if patient develops a new autoimmune disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Pancytopenia (rare), leukopenia, and thrombocytopenia have been reported. Monitor blood counts at 1, 3, and 6 months post therapy initiation and periodically thereafter. Events may recur with rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Rare cases of severe hepatic injury, including cases of hepatic failure requiring transplantation, have been reported in patients receiving interferon beta-1a; risk may be increased by ethanol use or concurrent therapy with hepatotoxic drugs. Some reports indicate symptoms began after 1 to 6 months of treatment. Transaminase elevations may be asymptomatic. Use with caution in patients with active or a history of liver disease, alcohol abuse, or increased serum ALT (&gt;2.5 times ULN) at baseline. Obtain liver function tests at 1, 3, and 6 months post therapy initiation and periodically thereafter. Treatment should be suspended immediately if jaundice or symptoms of hepatic dysfunction occur. Consider dose reductions or temporary discontinuation if ALT &gt;5 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Severe injection site reactions have occurred, including pain, erythema, edema, cellulitis, abscess, and necrosis. Necrosis may occur at single and multiple sites. Some reactions have occurred &ge;2 years after initiation; reactions typically resolve with conservative treatment (antibiotics or surgical intervention may be required). Patient and/or caregiver competency in injection technique should be confirmed and periodically re-evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: Interferons have been associated with psychiatric adverse events (psychosis, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms; use with caution in patients with depression. Patients exhibiting symptoms of depression or other severe psychiatric symptoms should be closely monitored and discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported (Hunt 2014; Mahe 2013; Rebif Canadian product labeling 2016). Some cases may occur after several years of therapy. Monitor for new onset hypertension, thrombocytopenia, or impaired renal function; discontinuation of therapy and prompt treatment may be necessary if TTP/HUS are confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease. Rare cases of new-onset cardiomyopathy and/or HF have been reported. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment or in those who abuse alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Thyroid abnormalities may develop with use; may worsen pre-existing thyroid conditions. Monitor thyroid function tests every 6 months or as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic progressive MS: Safety and efficacy have not been established for this use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some formulations contain albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases. Interferon beta-1a formulations that contain albumin are contraindicated in albumin-sensitive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging (prefilled syringe tip cap) may contain latex.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299523\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183433\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8565&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183435\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183448\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies; however, the possibility of adverse effects cannot be ruled out. Preliminary data from the Avonex pregnancy registry (published in abstract) do not show an increased risk of adverse fetal events when exposure occurs during pregnancy (Richman 2012; Tomczyk 2013); however, other studies have reported conflicting results. Until additional information is available, consideration should be given to discontinuing treatment if a woman becomes pregnant, or 1 month prior to becoming pregnant in women with mild disease (Coyle 2012; Houtchens 2013; Lu 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183449\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of interferon beta-1a are excreted in breast milk. Milk samples were obtained from 6 lactating women (6 to 23 months postpartum) receiving Avonex 30 mcg IM once weekly; sampling occurred at intervals for 72 hours after the dose. The highest reported concentration was 179 pg/mL and the relative infant dose was calculated to be &lt;1% of the maternal dose. Adverse events were not observed in the breastfeeding infants (Hale 2012). The manufacturer recommends that caution be exercised when administering interferon beta-1a to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183437\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Thyroid function tests, CBC with differential, transaminase levels, blood chemistries, symptoms of autoimmune disorders, signs/symptoms of psychiatric disorder (including depression and/or suicidal ideation), signs/symptoms of new onset/worsening cardiovascular disease, signs/symptoms of thrombotic microangiopathy (new-onset hypertension, thrombocytopenia, renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avonex: Frequency of monitoring for patients receiving Avonex has not been specifically defined; in clinical trials, monitoring was at 6-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rebif: CBC and liver function testing at 1-, 3-, and 6 months, then periodically thereafter. Thyroid function every 6 months (in patients with pre-existing abnormalities and/or clinical indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183427\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferon beta differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; alters the expression and response to surface antigens and can enhance immune cell activities. Properties of interferon beta that modify biologic responses are mediated by cell surface receptor interactions; mechanism in the treatment of MS is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183444\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Avonex: 12 hours (based on biological response markers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Avonex: 4 days (based on biological response markers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Avonex: ~19 hours (range: 8-54 hours); Rebif: 69 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Avonex (IM): ~15 hours (range: 6-36 hours); Rebif (SubQ): 16 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183447\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Auto-injector Kit</b> (Avonex Pen Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mcg/0.5 mL (1): $8,147.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Avonex Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mcg (1): $2,036.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe Kit</b> (Avonex Prefilled Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mcg/0.5 mL (1): $8,147.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Rebif Rebidose Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22 mcg/0.5 mL (0.5 mL): $728.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">44 mcg/0.5 mL (0.5 mL): $728.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Rebif Rebidose Titration Pack Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6X8.8 &amp; 6X22 mcg (4.2 mL): $8,736.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Rebif Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22 mcg/0.5 mL (0.5 mL): $728.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">44 mcg/0.5 mL (0.5 mL): $728.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Rebif Titration Pack Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6X8.8 &amp; 6X22 mcg (4.2 mL): $8,736.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183450\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avoneks (UA);</li>\n      <li>Avonex (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, MT, NL, NO, NZ, PE, PL, PT, PY, QA, RO, RU, SA, SE, SI, SK, TR, UY, VE);</li>\n      <li>Emaxen (EC);</li>\n      <li>Jumtab (PY);</li>\n      <li>Rebif (AE, AR, AU, BB, BH, BR, CH, CN, CR, CU, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, JO, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RO, SA, SE, SG, SI, SK, SV, TH, TW, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Avonex (interferon beta-1a) [prescribing information]. Cambridge, MA: Biogen Idec Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avonex (interferon beta-1a) [product monograph]. Mississauga, Ontario, Canada: Biogen Idec Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coyle PK, &ldquo;Pregnancy and Multiple Sclerosis,&rdquo; <i>Neurol Clin</i>, 2012, 30(3):877-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/22840794/pubmed\" target=\"_blank\" id=\"22840794\">22840794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26008947\"></a>Govern EM, Judge EP, Kavanagh E, Gaine S, Lynch T. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity? <i>Mult Scler Relat Disord</i>. 2015;4(3):284-286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/26008947/pubmed\" target=\"_blank\" id=\"26008947\">26008947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale TW, Siddiqui AA, and Baker TE, &ldquo;Transfer of Interferon &beta;-1a into Human Breastmilk,&rdquo; <i>Breastfeed Med</i>, 2012, 7(2):123-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/21988602/pubmed\" target=\"_blank\" id=\"21988602\">21988602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts. Interferon beta products &mdash; assessing the potential risk of plumonary arterial hypertension. Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/interferon-beta2-eng.php. Published November 2, 2016. Accessed November 16, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houtchens MK and Kolb CM, &ldquo;Multiple Sclerosis and Pregnancy: Therapeutic Considerations,&rdquo; <i>J Neurol</i>, 2013, 260(5):1202-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/22926165/pubmed\" target=\"_blank\" id=\"22926165\">22926165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. <i>N Engl J Med</i>. 2014;370(13):1270-1271.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs LD, Beck RW, Simon JH, et al, &ldquo;Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis. CHAMPS Study Group, <i>N Engl J Med</i>, 2000, 343(13):898-904.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu E, Wang BW, Guimond C, et al, &ldquo;Safety of Disease-Modifying Drugs for Multiple Sclerosis in Pregnancy; Current Challenges and Future Considerations for Effective Pharmacovigilance,&quot; <i>Expert Rev Neurother</i>, 2013, 13(3):251-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/23448215/pubmed\" target=\"_blank\" id=\"23448215\">23448215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahe J, Meurette A, Moreau A, et al. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. <i>Drug Des Devel Ther</i>. 2013;7:723-728.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/23950639/pubmed\" target=\"_blank\" id=\"23950639\">23950639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Panitch H, Goodin DS, Francis G, et al, &ldquo;Randomized, Comparative Study of Interferon Beta-1a Treatment Regimens in MS: The EVIDENCE Trial. EVIDENCE Study Group. Evidence of Interferon Dose-Response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group,&rdquo; <i>Neurology</i>, 2002, 59(10):1496-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/12451188/pubmed\" target=\"_blank\" id=\"12451188\">12451188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebif (interferon beta-1a) [prescribing information]. Rockland, MA: EMD Serono Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebif (interferon beta-1a) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richman S, Wallace K, Liu S, et al, &ldquo;Pregnancy Outcomes From the Avonex (Interferon Beta-1a) Pregnancy Exposure Registry,&rdquo; <i>Neurology</i>, 2012, 78 (meeting abstracts 1):P06.191.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomczyk S and Sperling B, &ldquo;Pregnancy Outcomes in Patients Exposed to Intramuscular Interferon Beta-1a (IM IFN&beta;-1a),&rdquo; <i>Neurology</i>, 2013, 80 (meeting abstracts):S30.006.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8565 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183458\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F183459\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183497\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F183461\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F183462\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14385980\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F183463\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14385978\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183440\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183424\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874830\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F183442\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183441\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F183506\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183431\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183445\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183428\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299523\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183433\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183435\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183448\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183449\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F183437\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F183427\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F183444\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F183447\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183450\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8565|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=interferon-beta-1a-patient-drug-information\" class=\"drug drug_patient\">Interferon beta-1a: Patient drug information</a></li></ul></div></div>","javascript":null}